

Antibiotics for the treatment of hepatic encephalopathy

Kavish R. Patidar · Jasmohan S. Bajaj

Received: 7 December 2012 / Accepted: 25 January 2013 / Published online: 8 February 2013
© Springer Science+Business Media New York 2013

Abstract The treatment of hepatic encephalopathy (HE) is complex and therapeutic regimens vary according to the acuity of presentation and the goals of therapy. Most treatments for HE rely on manipulating the intestinal milieu and therefore antibiotics that act on the gut form a key treatment strategy. Prominent antibiotics studied in HE are neomycin, metronidazole, vancomycin and rifaximin. For the management of the acute episode, all antibiotics have been tested. However the limited numbers studied, adverse effects (neomycin oto- and nephrotoxicity, metronidazole neurotoxicity) and potential for resistance emergence (vancomycin-resistant enterococcus) has limited the use of most antibiotics, apart from rifaximin which has the greatest evidence base. Rifaximin has also demonstrated, in conjunction with lactulose, to prevent overt HE recurrence in a multi-center, randomized trial. Despite its cost in the US, rifaximin may prove cost-saving by preventing hospitalizations for overt HE. In minimal/covert HE, rifaximin is the only systematically studied antibiotic. Rifaximin showed improvement in cognition, inflammation, quality-of-life and driving simulator performance but cost-analysis does not favor its use at the current time. Antibiotics, especially rifaximin, have a definite role in the management across the spectrum of HE.

Keywords Rifaximin · Neomycin · Covert hepatic encephalopathy · Metronidazole · Vancomycin · Economics

Introduction

Management of HE has traditionally been with non-absorbable disaccharides for lowering the production and absorption of

ammonia (Blei and Cordoba 2001). Antibiotics have been mainly used as alternatives to the non-absorbable disaccharides in improving HE symptoms (Bajaj 2010). This review will highlight the role of antibiotics in the acute treatment and prevention of HE obtained through a detailed literature, abstract and guidelines search for studies that responded to the MESH terms “antibiotics and hepatic encephalopathy”. There will also be a brief description of the role of antibiotics in treating infections as a precipitant of overt HE, on minimal or covert HE, and evaluation of economic considerations in antibiotic therapy.

Rationale

The prevention of production and absorption of gut-derived neurotoxins along with reduction in endotoxemia and inflammation underlie the rationale for antibiotic use in HE. A major component of these toxins is ammonia, while, other gut-derived products, oxindole, phenols, mercaptans, and short-chain fatty acids, have also been implicated (Riggio et al. 2010). It has also been shown that cirrhotic patients have significantly altered stool microbiome, which can also impact cognition (Bajaj et al. 2012a). Lowering systemic ammonia and reduction of inflammation and endotoxemia can be achieved through antimicrobials (Kalambokis et al. 2012; Jalan 2010; Sanyal et al. 2010). Based on this gut-specific action, most antibiotics used have been gut non-absorbable in nature. Neomycin, vancomycin, paromomycin, metronidazole, and recently rifaximin, have been shown to be effective in acute and chronic therapy of HE (Poh and Chang 2012).

Systemic antibiotic use for infections that can precipitate overt HE

Bacterial infections are significant precipitants of overt HE, especially spontaneous bacterial peritonitis, and in situations

K. R. Patidar · J. S. Bajaj (✉)
Division of Gastroenterology, Hepatology and Nutrition,
Virginia Commonwealth University and McGuire VA Medical
Center, 1201 Broad Rock Boulevard,
Richmond, VA, USA
e-mail: jsbajaj@vcu.edu

where bacterial translocation is increased such as an upper GI bleeding episode (Gustot et al. 2009). The recommended antibiotics in this situation depend on the infection and local microbial susceptibilities but are broad-spectrum, systemic agents that are aimed at the infection rather than HE itself (Bajaj 2010). In contrast, antibiotics specifically for HE are gut-specific and are not effective for treating potential infections during the acute episode.

Antibiotic use in covert and overt HE

These are antibiotics specifically directed towards HE; most studies pertaining to antibiotic use have concentrated on the acute overt HE episode or prevention of overt HE recurrence (Table 1). Only rifaximin has been studied for covert/minimal HE and therefore it will be discussed in the section pertaining to rifaximin.

Aminoglycosides (neomycin and ribostamycin)

Neomycin and ribostamycin are the aminoglycosides that have been studied. Only one study comparing ribostamycin to lactulose in 15 patients has been performed, that showed equivalence; rest have used neomycin. Neomycin has activity against most gram-negative aerobes, except pseudomonas, and staphylococcal species. It inhibits bacterial protein synthesis via binding to the bacterial 30S ribosomal subunit and in some reports, has also been shown to inhibit intestinal glutaminase. There is limited data on the effectiveness of neomycin, since its use predated our current concept of evidence-based or randomized trials and it was the standard to which lactulose was initially compared to when it was first studied. A randomized, double blind, controlled trial comparing neomycin versus placebo in acute HE demonstrated no significant difference in symptomatic improvement (Strauss et al. 1992). In addition, other randomized controlled studies comparing neomycin to lactulose found no significant difference between the two agents (Orlandi et al. 1981; Atterbury et al. 1978; Conn et al. 1977). Dosing of neomycin is usually 1,000 mg every 6 h for up to 6 days in an acute episode of overt HE and 1–2 g daily for chronic use.

Though neomycin is FDA approved for HE, its continued clinical use is not recommended given its extensive side-effect profile. Common adverse events include intestinal malabsorption, nephrotoxicity, and ototoxicity. These side effects are common in chronic use because systemic absorption is much higher in hepatic and renal failure, as compared to roughly 4 % for subjects without this organ dysfunction, increasing the systemic exposure (Fig. 1). It is due to these side effects and lack of demonstrated clinical benefit that neomycin use has fallen out of favor for HE treatment.

Metronidazole, vancomycin and paromomycin

There have been limited studies on the efficacy of metronidazole and vancomycin in the management of HE. In a small study by Morgan et al., 11 mild to moderate HE patients and seven chronically affected HE patients were treated for 1 week with 250 mg oral dose of metronidazole twice daily with similar efficacy as neomycin (Morgan et al. 1982). However given its prolonged rate of elimination in HE patients and increased risk for irreversible peripheral neurotoxicity metronidazole is not recommend for the management of an acute episode or for chronic management of HE (Loft et al. 1987).

Oral vancomycin, on the other hand, may be safer for the management for an acute HE episode, and has been studied in a limited group of HE patients who were resistant to lactulose (Tarao et al. 1990). Nevertheless, the limited studies, high expense, and with increased prevalence of vancomycin-resistant enterococci and other bacterial resistance, preclude its routine use (Fernández et al. 2012; Bajaj et al. 2012b).

Paromomycin has been compared with rifaximin for the treatment of acute episodes of HE in three studies. Only one trial showed improvement in cognitive testing that was greater in rifaximin; rest showed equivalence (Marco et al. 1984; Testa et al. 1985; Parini et al. 1992). Metronidazole, paromomycin and vancomycin are not FDA approved for treatment of overt HE.

Rifaximin

Rifaximin is gut-specific antimicrobial agent for the management of HE that is FDA-approved for prevention of overt HE recurrence. It has a broad spectrum of activity against both gram positive and gram negative organisms, and specifically against anaerobic enteric bacteria (Jiang and DuPont 2005). It binds to the b-subunit of the bacterial DNA-dependent RNA polymerase and disrupts RNA synthesis. However, unlike its derivative, rifamycin, less than 1 % is absorbed systemically after oral administration, resulting in greater concentration in the gastrointestinal tract. This systemic exposure increases with worsening liver disease severity (Fig. 1) (U.S. Food and Drug Administration 2010). It also has minimal effects on normal gut flora, though increased doses were shown to initially decrease GI flora such as *enterococcus*, *Escherichia coli*, *Lactobacillus spp.*, *Bacteroides spp.*, *Bifidobacterium spp.* and *Clostridium perfringens* all of which returned to initial values after a wash-out period (Brigidi et al. 2012).

Rifaximin has minimal side effects – headache, flatulence, abdominal pain, constipation, nausea, and vomiting – and no reported drug interactions make it relatively safe. It has been demonstrated to be superior to lactulose and other antimicrobials in numerous trials in patients with mild to moderate

Table 1 Summary of overt HE acute, long-term and recurrence trials with antibiotics


Type of study	Number of trials and sample size	Results
Aminoglycosides (neomycin or ribostamycin)		
Acute therapy (5–30 days)		
Vs placebo	1 (39)	Time to HE grade change in which both were equivalent in 7 days (Strauss et al.)
Neomycin vs non-absorbable disaccharides	2 (105)	Equivalent efficacy compared to lactulose using mental status, ammonia, EEG and PSE index (Orlandi et al, Atterbury et al. and Blanc et al.)
Chronic therapy (>30 days)		
Vs non-absorbable disaccharides	2 (48)	Equivalent efficacy compared to lactulose using mental status, ammonia, EEG and PSE index (Conn et al. 1997)
Both acute and chronic		
Vs non-absorbable disaccharides	1 (173)	Equivalent efficacy (Orlandi et al. 1981 Cochrane)
Vancomycin [all acute therapy (5–30 days)]		
Vs lactulose	2 (72)	Improvement in mental status in one trial of 12 patients but equivalence in the others
Metronidazole (both acute and chronic)		
Vs. neomycin	1 (18)	Equivalence in EEG, ammonia and clinical status
Paromomycin (all acute therapy studies, 5–30 days)		
Vs. rifaximin	3 (82)	Ammonia reduced in both groups; two trials showed equivalence while one showed that rifaximin was superior to paromomycin with respect to psychometric tools
Rifaximin		
Acute therapy (5–30 days)		
Rifaximin vs. placebo	1 (93)	Asterixis improved only with rifaximin. PSE index, mental status, and intellectual function improved similarly in both groups
Rifaximin 200 mg vs 400 mg vs 800 mg	1 (54)	PSE index improved only in 400-mg and 800-mg groups.
Rifaximin vs other antibiotics	7 (227)	Ammonia improved more with rifaximin than neomycin (1 RCT) or similarly in both (6 RCTs). PSE index improved similarly in both groups (1 RCT). Intellectual function or mental status improved similarly in both groups (5 RCTs). Asterixis improved faster with rifaximin than with neomycin (1 RCT).
Rifaximin vs non-absorbable disaccharides	5 (276)	Higher ammonia improvement with rifaximin (3 RCTs) or similarly in both groups (2 RCTs). PSE or symptoms improved more with disaccharides
Long-term studies (3–6 months cyclical)		
Rifaximin vs non-absorbable disaccharides	2 (80)	Ammonia and mental status improved with both trials with all strategies compared to baseline. Higher improvement in PSE index, EEG and mental status with rifaximin. In the second study, rifaximin+/-lactitol did better than lactitol alone with mental status.
Rifaximin vs. neomycin	1(60)	Improvement in psychometric/neuro-physiologic tests, mental status and ammonia were similar across both groups.
Prevention of recurrence		
Rifaximin vs. placebo	1 (299)	Reduction in recurrent HE episodes and hospitalization in the rifaximin group with significantly higher improvement in neuro-physiological, quality-of-life and ammonia in the rifaximin group. 91 % of patients were on lactulose in both groups.

Adapted from Bajaj JS Hepatol 2010 with permission (Bajaj and Riggio 2010). PSE index: a composite score for HE consisting of $100 \times [\text{Mental status (Conn score)} \times 3 + \text{asterixis grade} \times 1 + \text{NCT grade} \times 1]$

severe HE (Festi et al. 1993; Bucci and Palmieri 1993; Massa et al. 1993; Fera et al. 1993; Mas et al. 2003; Leevy and

Phillips 2007; Paik et al. 2005; Alcorn 2008; Bajaj and Riggio 2010) (Table 1).

Fig. 1 Pharmacokinetics of rifaximin compared to neomycin and rifampin (U.S. Food and Drug Administration 2010). The figure shows that the systemic exposure to rifaximin compared to neomycin and rifampin in healthy individuals. The comparative exposure to rifaximin increases with worsening liver disease severity



In a randomized, double-blind, placebo controlled prospective trial, Bass et al. compared rifaximin, dosed at 550 mg twice daily, to placebo over 6 months in patients with two prior overt HE episodes and showed a reduction in risk of developing HE (Bass et al. 2010). In addition the risk of hospitalization was significantly reduced in the rifaximin group. This study showed reduction in venous ammonia and improvement in health-related quality of life in patients randomized to rifaximin (Sanyal et al. 2010; Sanyal et al. 2011). Additionally a recent study by Neff et al, showed that rifaximin used for greater than 6 months to be an effective agent for HE, particularly in patients with a model for end-stage liver disease (MELD) score less than 20 (Neff et al. 2012).

Rifaximin is one of the few antimicrobial agents that has been tested in patients with covert/minimal HE. The RIME trial randomized minimal HE patients into rifaximin and placebo and found that rifaximin therapy was associated with a significant improvement in cognitive performance and health-related quality of life compared to placebo (Sidhu et al. 2011). Another study in minimal HE extended these findings on to the real-world outcomes of driving, in which patients randomized to rifaximin not only improved their cognition, but also significantly bettered their driving simulator performance and reduced systemic inflammation, but only psycho-social aspects of quality of life improved (Bajaj et al. 2011).

Economic analysis for HE treatment with antibiotics

The economic analysis of HE is important given the daunting and ever-increasing costs of health care. Therefore a pragmatic approach includes the cost analysis of the drug as well as the savings if subsequent negative outcomes, i.e. hospitalizations are prevented (Prakash and Mullen 2010; Shawcross et al. 2011; Stepanova et al. 2012; Poordad 2007). As with any management for a medical condition, the risks and benefits have to be considered. Both non-absorbable disaccharides and neomycin have dose limiting side-effects and ambiguous

effectiveness. While, on the other hand, rifaximin, has a more tolerable side-effect profile as well as being more efficacious, but is more expensive.

A comprehensive decision analysis published by Huang et al. (2007) addressed this dilemma through a cost effectiveness of 6 different strategies in the management of HE. The six arms were: (1) no HE treatment; (2) lactulose monotherapy (3) lactitol monotherapy; (4) neomycin monotherapy; (5) rifaximin monotherapy; and (6) up front lactulose with crossover to rifaximin if there was a poor response or intolerance to lactulose (Huang et al. 2007). Through using decision-analysis software, the study concluded that the “do nothing” arm was the least efficacious and rifaximin salvage was most efficacious. However it was also noted that rifaximin monotherapy was not cost effective and that lactulose monotherapy and rifaximin salvage therapy was less expensive and more effective than alternate therapies. Conversely, studies have shown that since rifaximin may be associated with a lower rate of hospitalizations, this could result in overall cost-saving since the costs of hospitalizations far outweigh the costs of the therapy (Neff et al. 2007; Mantry and Munsaf 2010). In minimal or covert HE however, where hospitalizations are few and the therapy has to continue for a longer period potentially, rifaximin was not cost-saving for the prevention of motor vehicle accidents compared to lactulose from a societal perspective (Bajaj et al. 2012c).

Conclusions

Antimicrobial agents form a substantial component of the armamentarium against HE. Although several agents have been used, the antimicrobial agent with the most published experience is rifaximin. The use of rifaximin has evolved over several decades and is one of the most widely used antibiotics for overt HE. However further studies into appropriate place of antimicrobials as first or second line therapeutic strategies for HE are needed.

References

- Alcorn J (2008) Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. *ACP J Club* 149(5):11
- Atterbury CE, Maddrey WC, Conn HO (1978) Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. *Am J Dig Dis* 23:398–406
- Bajaj JS (2010) Review article: the modern management of hepatic encephalopathy. *Aliment Pharmacol Ther* 31(5):537–547
- Bajaj JS, Riggio O (2010) Drug therapy: rifaximin. *Hepatology* 52(4):1484–1488
- Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. *Gastroenterology* 140(2):478–487
- Bajaj JS, Hyleman PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM (2012a) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. *Am J Physiol Gastrointest Liver Physiol* 303(6):G675–G685
- Bajaj JS, O’Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS (2012b) Second infections independently increase mortality in hospitalized patients with cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. *Hepatology* 56(6):2328–2335
- Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012c) Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. *Hepatology* 55(4):1164–1171
- Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 362(12):1071–1081
- Blei AT, Cordoba J (2001) Hepatic encephalopathy. *Am J Gastroenterol* 96:1968–1976
- Brigidi P, Swennen E, Rizzello F, Bozzolascio M, Matteuzzi D (2012) Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. *J Chemother* 14(3):290–295
- Bucci L, Palmieri GC (1993) Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. *Curr Med Res Opin* 13:109–118
- Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. *Gastroenterology* 72(4 Pt 1):573–583
- Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A (1993) Rifaximin in the treatment of hepatic encephalopathy. *Eur J Clin Res* 4(1):57–66
- Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V (2012) Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. *Hepatology* 55(5):1551–1561
- Festi D, Mazzella G, Orsini M, Scottili S, Sangermano A, Li Bassi S, Ferrieri A, Falcucci M, Grossi L, Marzio L, Roda E (1993) Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. *Curr Ther Res* 54(5):598–609
- Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R (2009) Severe Sepsis in cirrhosis. *Hepatology* 50(6):2022–2033
- Huang E, Esrailian E, Spiegel BMR (2007) The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. *Aliment Pharmacol Ther* 26:1147–1161
- Jalan R (2010) Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic? *J Hepatol* 53(3):580–582
- Jiang ZD, DuPont HL (2005) Rifaximin: in vitro and in vivo antibacterial activity—a review. *Chemotherapy* 51(Suppl 1):67–72
- Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsiansos EV (2012) Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. *Clin Gastroenterol Hepatol* 10(7):815–818
- Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. *Dig Dis Sci* 52:737–741
- Loft S, Sonne J, Dossing M, Andreasen PB (1987) Metronidazole pharmacokinetics in patients with hepatic encephalopathy. *Scand J Gastroenterol* 22(1):117–123
- Mantry PS, Munsaf S (2010) Rifaximin for the treatment of hepatic encephalopathy. *Transplant Proc* 42(10):4543–4547
- Marco F, Amato PS, D’Arienzo A (1984) Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. *Curr Ther Res* 36:668–674
- Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A (2003) Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. *J Hepatol* 38(1):51–58
- Massa P, Vallerino E, Doderio M (1993) Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. *Eur J Clin Res* 4:7–18
- Morgan MH, Read AE, Speller DC (1982) Treatment of hepatic encephalopathy with metronidazole. *Gut* 23(1):1–7
- Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K (2007) Outcomes in adult and pediatric liver transplantation among various ethnic groups. *Transplant Proc* 39(10):3204–3206
- Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N (2012) Durability of rifaximin response in hepatic encephalopathy. *J Clin Gastroenterol* 46(2):168–171
- Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A, Dobrilla G, Cavallini G (1981) Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. *Dig Dis Sci* 26(6):498–506
- Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM (2005) Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. *Yonsei Med J* 46(3):399–407
- Parini P, Cipolla A, Ronci M, Antonio M, Salzetta A, Mazzella G, Roda E (1992) Effect of paromomycin in the treatment of portal-systemic encephalopathy. *Curr Ther Res* 52:34
- Poh Z, Chang PE (2012) A current review of the diagnostic and treatment strategies of hepatic encephalopathy. *Int J Hepatol* 2012:480309
- Poordad FF (2007) Review article: the burden of hepatic encephalopathy. *Aliment Pharmacol Ther* 1:3–9
- Prakash R, Mullen KD (2010) Mechanisms, diagnosis and management of hepatic encephalopathy. *Nat Rev Gastroenterol Hepatol* 7:515–525
- Riggio O, Mannaioni G, Ridola L, Angeloni S, Merli M, Carlà V, Salvatori FM, Moroni F (2010) Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the

- pathophysiology of hepatic encephalopathy. *Am J Gastroenterol* 105(6):1374–1381
- Sanyal A, Bass N, Poorad F, Sheikh MY, Mullen K, Sigal S, Frederick T, Brown, Jr R, Bhandari B, Sedghi S, Merchant K, Huang S, Shaw A, Bortey E, Forbes W (2010) Rifaximin decreases venous ammonia concentrations and time-weighted average ammonia concentrations correlate with overt hepatic encephalopathy (HE) as assessed by Conn Score in a 6-months study. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver Abstract 195
- Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study. *Aliment Pharmacol Ther* 34(8):853–861
- Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA (2011) Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. *J Hepatol* 54:640–649
- Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). *Am J Gastroenterol* 106(2):307–316
- Stepanova M, Mishra A, Venkatesan C, Younossi ZM (2012) In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. *Clin Gastroenterol Hepatol* 10(9):1034–1041
- Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, de Sá MF (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. *Hepatogastroenterology* 39(6):542–545
- Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T, Karube H, Nomoto T, Mizuno T, Shindo K (1990) Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. *Gut* 31(6):702–706
- Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G (1985) *Drugs Exp Clin Res* 11(6):387–392
- U.S. Food and Drug Administration (2010) Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting 23 February 2010. <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf>. Accessed 3 December 2012